The use of Flt3 ligand as an adjuvant for hepatitis B vaccination of healthy adults

被引:19
作者
Evans, TG
Hasan, M
Galibert, L
Caron, D
机构
[1] Univ Calif Davis, Div Infect Dis, PSSB, Sacramento, CA 95817 USA
[2] Univ Rochester, Sch Med & Dent, Rochester, NY 14627 USA
[3] Immunex Corp, Seattle, WA USA
关键词
vaccination; cytokines; viral;
D O I
10.1016/S0264-410X(02)00454-1
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A phase I/II clinical trial was carried out to determine the safety of Flt3 ligand used as a vaccine adjuvant when administered to healthy human volunteers on two different schedules. In the first phase of this study, Flt3 ligand was administered SQ at a dose of 20 mug/kg (to a maximum of 1500 mug) every day (N = 10) or every other day (N = 10) for I week. The Flt3 ligand injection series was followed 1 day later by the first of three vaccinations with the licensed hepatitis B vaccine. In the second phase of the trial, 30 volunteers received either Flt3 ligand or placebo on the alternate day schedule in a randomized, double-blind design. The Flt3 ligand injections were safe and very well-tolerated. The number of lineage negative, HLA-DRhi, CD11c(+), CD123(-) dendritic cells (DCs) increased 23-fold, and the lineage negative, HLA-DRhi, CD11c(-), CD123bright pre-DCs increased 6-fold. There was an associated increase in monocytes and WBCs in the Flt3 ligand recipients. Despite the marked increase in peripheral circulating dendritic cells, no increase was observed in the hepatitis B antibody titers induced after vaccination. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:322 / 329
页数:8
相关论文
共 37 条
[1]   Prediction of response to hepatitis B vaccine in health care workers: Whose titers of antibody to hepatitis B surface antigen should be determined after a three-dose series, and what are the implications in terms of cost-effectiveness? [J].
Alimonos, K ;
Nafziger, AN ;
Murray, J ;
Bertino, JS .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (03) :566-571
[2]   Immunobiology of dendritic cells [J].
Banchereau, J ;
Briere, F ;
Caux, C ;
Davoust, J ;
Lebecque, S ;
Liu, YT ;
Pulendran, B ;
Palucka, K .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :767-+
[3]  
Banchereau J, 1997, TRANSFUS SCI, V18, P313
[4]  
Borges L, 1999, J IMMUNOL, V163, P1289
[5]   Hematologic effects of flt3 ligand in vivo in mice [J].
Brasel, K ;
McKenna, HJ ;
Morrissey, PJ ;
Charrier, K ;
Morris, AE ;
Lee, CC ;
Williams, DE ;
Lyman, SD .
BLOOD, 1996, 88 (06) :2004-2012
[6]   Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children [J].
Chang, MH ;
Chen, CJ ;
Lai, MS ;
Hsu, HM ;
Wu, TC ;
Kong, MS ;
Liang, DC ;
Shau, WY ;
Chen, DS .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (26) :1855-1859
[7]  
Chen KY, 1997, CANCER RES, V57, P3511
[8]   Polyethylene glycol-modified GM-CSF expands CD11bhighCD11chigh but not CD11blowCD11chigh murine dendritic cells in vivo:: A comparative analysis with Flt3 ligand [J].
Daro, E ;
Pulendran, N ;
Brasel, K ;
Teepe, M ;
Pettit, D ;
Lynch, DH ;
Vremec, D ;
Robb, L ;
Shortman, K ;
McKenna, HJ ;
Maliszewski, CR ;
Maraskovsky, E .
JOURNAL OF IMMUNOLOGY, 2000, 165 (01) :49-58
[9]   Polyomavirus-infected dendritic cells induce antiviral CD8+ T lymphocytes [J].
Drake, DR ;
Moser, JM ;
Hadley, A ;
Altman, JD ;
Maliszewski, C ;
Butz, E ;
Lukacher, AE .
JOURNAL OF VIROLOGY, 2000, 74 (09) :4093-4101
[10]  
Drakes ML, 1997, J IMMUNOL, V159, P4268